Engineering Crystallinity Gradients for Tailored CaO2 Nanostructures: Enabling Alkalinity-Reinforced Anticancer Activity with Minimized Ca2+/H2O2 Production
Source abstract
Abstract
CaO 2 nanoparticles (CNPs) can produce toxic Ca 2+ and H 2 O 2 under acidic pH, which accounts for their intrinsic anticancer activity but at the same time raises safety concerns upon systemic exposure. Simultaneously realizing minimized Ca 2+ /H 2 O 2 production and enhanced anticancer activity poses a dilemma. Herein, we introduce a “crystallinity gradient-based selective etching” (CGSE) strategy, which is realized by creating a crystallinity gradient in a CNP formed by self-assembled nanocrystals. The nanocrystals distributed in the outer layer have a higher crystallinity and thus are chemically more robust than those distributed in the inner layer, which can be selectively etched. CGSE not only leads to CNPs with tailored single- and double-shell hollow structures and metal-doped compositions but more surprisingly enables significantly enhanced anticancer activity as well as tumor growth inhibition under limited Ca 2+ /H 2 O 2 production, which is attributed to an alkalinity-reinforced lysosome-dependent cell death pathway.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · MXene and MAX Phase Materials · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China
Institute of Optoelectronics, Fudan University, Shanghai, 200433, China
Funding
National Health and Medical Research Council
References (34)
Show source-provided references
1. 10.1016/S2666-1683(20)33832-510.1016/S2666-1683(20)33832-5 ↗
2. 10.1016/j.biomaterials.2021.12108910.1016/j.biomaterials.2021.121089 ↗
3. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
4. 10.1016/j.actbio.2020.12.03610.1016/j.actbio.2020.12.036 ↗
5. 10.1002/cmdc.20210010810.1002/cmdc.202100108 ↗
6. 10.1126/science.111439710.1126/science.1114397 ↗
7. 10.1186/s12951-021-01055-410.1186/s12951-021-01055-4 ↗
8. 10.1002/smll.20190211810.1002/smll.201902118 ↗
9. 10.1038/s41467-020-15591-410.1038/s41467-020-15591-4 ↗
10. 10.1021/jacs.6b0178410.1021/jacs.6b01784 ↗
11. 10.1002/advs.20210024110.1002/advs.202100241 ↗
12. 10.1021/ja203316q10.1021/ja203316q ↗
13. 10.1002/adfm.20160119310.1002/adfm.201601193 ↗
14. 10.1021/acsnano.1c0730810.1021/acsnano.1c07308 ↗
15. 10.1016/j.jart.2017.02.00710.1016/j.jart.2017.02.007 ↗
16. 10.1016/0165-9936(91)85111-410.1016/0165-9936(91)85111-4 ↗
17. 10.7150/thno.3983110.7150/thno.39831 ↗
18. 10.1063/1.492145210.1063/1.4921452 ↗
19. 10.1016/j.msea.2008.09.00610.1016/j.msea.2008.09.006 ↗
20. 10.1039/c0cp00031k10.1039/c0cp00031k ↗
21. 10.1002/adma.20030038110.1002/adma.200300381 ↗
22. 10.2307/154356910.2307/1543569 ↗
23. 10.1002/ange.20130858910.1002/ange.201308589 ↗
24. 10.1002/ange.20170160410.1002/ange.201701604 ↗
25. 10.1002/adma.20200742610.1002/adma.202007426 ↗
26. 10.1002/anie.20220490410.1002/anie.202204904 ↗
27. 10.1016/j.biomaterials.2021.12108010.1016/j.biomaterials.2021.121080 ↗
28. 10.1021/acs.nanolett.0c0477810.1021/acs.nanolett.0c04778 ↗
29. 10.1016/j.biomaterials.2022.12174610.1016/j.biomaterials.2022.121746 ↗
30. 10.1021/jacs.7b1069410.1021/jacs.7b10694 ↗
31. 10.1021/acsami.1c1330410.1021/acsami.1c13304 ↗
32. 10.1186/1743-8977-2-810.1186/1743-8977-2-8 ↗
33. 10.1016/j.ccr.2013.08.00310.1016/j.ccr.2013.08.003 ↗
34. 10.3390/curroncol2803018310.3390/curroncol28030183 ↗